Trial Profile
Phase Ⅱ trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) in combination with capecitabine as first-line therapy in Chinese patients with HER2-negative metastatic breast cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2016
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Paclitaxel (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 21 Aug 2016 Status changed from not yet recruiting to recruiting.
- 18 Mar 2014 New trial record